EPO and Thrombocytopenia: Ruxolitinib inhibits normal erythropoietin and thrombopoietin signaling through JAK2 (through the erythropoietin and thrombopoietin receptors, respectively) [6], often resulting in dose-dependent anemia and thrombocytopenia [21, 61].